OBJECTIVE:To observe the efficacy and safety of Aidi injection combined with oxaliplatin and tegafur gimeracil oteracil potassium in the treatment of advanced colorectal cancer. METHODS:100 patients with advanced colorectal cancer were ran-domly divided into control group and observation group. Control group was treated with Tegafur gimeracil oteracil potassium cap-sule,body surface area1.50 m2,60 mg,it was orally tak-en after breakfast and dinner d1-28,the drug was stopped for 14 d after 28 d treatment+oxaliplatin 85-130 mg/m2 adding into 500 ml of 5% Glucose injection by intravenous infusion for 2 h. Observation group was additionally treated with Aidi injection 100 ml add-ing into 500 ml of 5% Glucose injection by intravenous infusion,once a day,d1-7,which was repeated every 14 d and was twice. The clinical efficacy,toxicity reactions,improvement of life quality and one-year survival rates in the two groups were observed. RESULTS:There was no statistically significant difference in the total effective rate between 2 groups (P>0.05). The improve-ment rate of life quality and one-year survival rate in the observation group were significantly higher than control group,the inci-dence rates of granulocytopenia,platelet decline,oral ulcer and peripheral neurotoxicity in observation group were significantly low-er than control group, there was significant difference between 2 groups (P1.50 m2,60 mg,早晚餐后口服,d1~28,后停药14 d+奥沙利铂85~130 mg/m2加入5%葡萄糖注射液500 ml中,静脉滴注2 h,d1;观察组患者在对照组治疗的基础上加用艾迪注射液100 ml加入5%葡萄糖注射液500 ml,静脉滴注,每日1次,d1~7,间隔14 d重复1次,共2次.观察两组患者的临床疗效,毒性反应,生存质量改善情况和1年生存率.结果:两组患者总有效率比较,差异无统计学意义(P>0.05).观察组患者生存质量提高率、1年生存率均显著高于对照组,粒细胞减少、血小板下降、口腔溃疡、外周神经毒性总发生率均显著低于对照组,差异均有统计学意义(P<0.05).结论:艾迪注射液辅助奥沙利铂联合替吉奥治疗晚期结直肠癌较奥沙利铂联合替吉奥的生存质量和1年生存率均较高,且安全性更好.
展开▼
